Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY1128688 Dose-Response Study in Symptomatic Endometriosis
NCT03373422Phase 2Terminated
- Sponsor
- Bayer
- Start
- Nov 2017
- Primary completion
- Jul 2018
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 13
01
Overview
A Phase 2 trial of BAY1128688 in endometriosis, sponsored by Bayer. Started Nov 2017; status: terminated.
02
Drugs
BAY1128688
03
Conditions
endometriosis
Beyond the preview
Go deeper on NCT03373422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03373422.